Insulet reported quarterly EPS of $1.42, beating the Zacks Consensus Estimate of $1.14 by $0.28 per share and up from $1.02 a year ago. The result points to improved profitability and a solid earnings beat for the diabetes device maker. This is likely to be supportive for the stock, though the article provides no revenue or guidance update.
Insulet reported quarterly EPS of $1.42, beating the Zacks Consensus Estimate of $1.14 by $0.28 per share and up from $1.02 a year ago. The result points to improved profitability and a solid earnings beat for the diabetes device maker. This is likely to be supportive for the stock, though the article provides no revenue or guidance update.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.34
Ticker Sentiment
